Parkinson Disease

Tavapadon's phase 3 success complements ongoing monotherapy trials, addressing the need for effective and well-tolerated PD therapies.

Patients experienced improvements in ON/OFF time and motor function, with favorable tolerability, paving the way for a phase 2 trial.

Neal K. Shah, CEO of CareYaya Health Technologies, an AI innovator in neurological care, discussed how technology is poised to transform the fight against Parkinson, with the potential to improve millions of lives and advance health equity.

Even at the highest modal dose range, findings from the phase 3 RISE-PD trial showed that IPX203 did not increase safety risks for patients with Parkinson disease over time.

SPN-830, an apomorphine infusion device, had its new drug application submitted using data from the phase 3 TOLEDO trial.

Findings from a recent study revealed the significant influence of lysosomal polygenic burden on cognitive decline in patients Parkinson disease who also have a low risk of Alzheimer disease.

Although results from the phase 2 LixiPark trial showed that lixisenatide may slow motor symptom progression in early Parkinson disease, reported gastrointestinal adverse effects raise some safety considerations.

The randomized, double-blind, placebo-controlled trial failed to show any beneficial symptomatic effect of 4-month treatment with 1.75–3.5 mg/day bumetanide on Parkinson disease.

The findings were consistent with the chemical's known carcinogenicity and supportive of the emerging preclinical and epidemiological evidence that ties TCE exposure to patients with PD.

A recent study revealed that digital composite measures for bradykinesia outperformed traditional assessment methods for Parkinson disease over a 12-month period.

At AD/PD 2024, AC Immune SA presented an update on the company's phase 2 VacSYn trial assessing ACI-7104.056, an anti-α-synuclein active immunotherapy, for patients with Parkinson disease.

It’s hard to be in medicine at the moment, and one day’s recognition is not enough. As your peer, I honor my fellow physicians today and every day.

New data presented at the 2024 AD/PD Conference revealed the potential of smartphone speech analysis metrics as a biomarker for hypokinetic dysarthria in early Parkinson disease.

Recent data highlighted the benefit of Gain Therapeutics’ GT-02287 mechanism of action in alleviating endoplasmic reticulum stress and enhancing lysosomal enzyme activity.

A phase 2a trial demonstrated significant cognitive improvement in patients with mild cognitive impairment or mild dementia from Alzheimer or Parkinson disease through combination adrenergic activator therapy.

Zoltan Mari, MD, dives deeper into tremors, a troublesome feature of PD, and what devices are available and upcoming to diagnose, monitor, and control tremors.

Zoltan Mari, MD, reviews the available wearable devices used to monitor bradykinesia and dyskinesia in patients with PD, as well as benefits and challenges associated with the devices.

The phase 2 study for risvodetinib in Parkinson disease aims to halt disease progression and reverse functional loss.

This complex waste clearance pathway within the CNS plays a crucial role in maintaining brain homeostasis, as a mechanism of protein waste removal alongside autophagy and protein aggregate ubiquitination.

In collaboration with Robert A. Hauser, MD, MBA, the survey aims to understand the impact of tremors in patients with Parkinson disease.

A 24-hour subcutaneous infusion of ND0612 was superior to oral immediate-release levodopa–carbidopa at increasing on time without troublesome dyskinesia and reducing off time in adults with Parkinson disease.

New findings from a phase 1 trial presented at AD/PD 2024 showed that UB-312 antibodies decrease α-synuclein levels in the cerebrospinal fluid of patients with Parkinson disease.

Over an 18-month period, patients demonstrated significant increases in ON time with bemdaneprocel, even after stopping immunosuppressives 1 year into treatment.

New findings from a phase 1b/2a study showed that NodThera's NT-0796, an oral NLRP3 inflammasome inhibitor, reduced inflammatory biomarkers among patients with Parkinson disease.

Tim Siegert, PhD, chief operating officer and co-founder of Allyx Therapeutics, provided commentary on the recently announced positive phase 1b results for ALX-001, an agent in development for Alzheimer and Parkinson disease.

An expert neurologist provides an overview of exablate neuro, an ultrasound device used to control physical symptoms of PD. He also reviews study results and ongoing clinical studies.

Zoltan Mari, MD, leads a discussion on the benefits of wearable devices in Parkinson’s Disease (PD), and emphasizes the major public health impact of the disease.

Building on positive phase 1a data, ALX-001 demonstrated target engagement of mGluR5 receptor and maintained a safe profile across multiple doses.

The national medical advisor for the Parkinson's Foundation discussed the importance of continuous and ‘spaced’ physical therapy for Parkinson disease, highlighting the underutilization of this approach.

A recent study showed that a short self-screening questionnaire boasted high sensitivity and specificity for identifying psychosis among patients with Parkinson disease.